Denali Therapeutics Inc. Common Stock — Quarterly Financial Statements (NASDAQ:DNLI) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Market Capitalization 3.3606 B
Employee 503
Founded 2013
CEO N/A
Website www.denalitherapeutics.com
Headquarter Delaware, United States
FIGI BBG008P7F869
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

3.36 B Market capitalization

Haberler

Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.

Denali Therapeutics, FDA onayı sonrası telif anlaşmasından 200 milyon dolar aldı

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up

H.C. Wainwright, Denali Therapeutics için hedef fiyatı 42 dolara yükseltti

FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript

Stifel, Denali Therapeutics için hedef fiyatı yükseltti

Goldman Sachs, Denali Therapeutics için hisse hedefini yükseltti

BTIG, Denali Therapeutics için hedef fiyatı 38 dolara yükseltti

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

Oppenheimer, FDA onayı sonrası Denali hedefini yükseltti